Cancer patients are commonly treated by external radiotherapy with ionizing radiation. In this approach only the macroscopic disease is treated, healthy tissues are damaged and significant adverse side effects occur. Radiopharmaceuticals are agents that can transport radiotoxic doses of radionuclides to tumors and metastatic sites. The compounds licensed by Calidum Inc. are directed to cancer cells via active transport mechanisms and are unique in that they can serve as a vehicle for targeted diagnostic radionuclides (SPECT and PET imaging) as well as targeted therapeutic radionuclides allowing the creation of multiple product lines of truly personalized medicine “theranostic” solutions.



Calidum’s technologies provide compelling differentiation:

  • are diagnostic as well as therapeutic
  • allow concomitant detection of tumors and assessment of their aggressiveness
  • can help distinguish indolent from progressive disease
  • are radiotoxic only to cells that express the targeted receptor and make DNA when RTDT is present
  • kill multidrug resistant and radioresistant cancer cells
  • are non-immunogenic allowing repeated dosing
  • are administered at extremely low doses of nanograms per kg body weight guaranteeing minimal pharmacologic toxicities
  • can be used as adjuvants without increasing overall toxicity of the primary treatment
  • have the lock-in-mechanism that traps RTDT in targeted cancer cells
  • are compatible with the individualized treatment strategy that uses diagnostic imaging to identify cancer patients that may benefit from molecular radiotherapy
  • FDA-approved IND application available for testing in the context of prostate cancer